Androgen Receptor Signalling Inhibitors – Post-Chemotherapy, Pre-Chemotherapy and now in castration sensitive prostate cancer - ERC -6.15.21
Signaling Inhibitor)
********************************************************
[i]For the purposes of this review, we will focus our discussion on the newer, more effective ARSIs: specifically, the CYP17 inhibitor abiraterone and the 2nd generation AR ligand-binding domain (LBD) antagonists (antiandrogens) enzalutamide
Signaling Inhibitor)
********************************************************
[i]For the purposes of this review, we will focus our discussion on the newer, more effective ARSIs: specifically, the CYP17 inhibitor abiraterone and the 2nd generation AR ligand-binding domain (LBD) antagonists (antiandrogens) enzalutamide